Annual Meeting Materials
Latest Financial Results
Q3 2024
Quarter Ended Sep 30, 2024
Latest Annual Filing
For Fiscal Year Ending Dec 31, 2023
Report Links
Latest News
Email Alerts
Sign up today and receive company updates straight to your inbox.
Company Overview
Lantern Pharma is a clinical stage biotechnology company focused on innovating the cancer drug development process by using advanced genomics, machine learning, and artificial intelligence ("A.I."). Our A.I. platform, known as RADR®️, currently includes more than 100 billion data points, and uses big data analytics and machine learning to rapidly uncover biologically relevant genomic signatures correlated to drug response, and then to identify the cancer patients that we believe may benefit most from our compounds. RADR®️ is also used by Lantern and its collaborators to 1) develop and position new drugs and 2) to rescue and reposition drug candidates that others have tried, but failed, to develop.
Lantern’s current portfolio consists of three lead drug candidates and an ADC program across 12 cancer indications, including one lead product candidate in phase 2 clinical testing and recently initiated phase 1 clinical programs for two additional lead product candidates. Lantern seeks out experienced industry partners, world-class scientific advisors and innovative clinical-regulatory approaches to assist with its objective of delivering cancer therapies to patients as quickly and cost-effectively as possible. This data-driven, genomically-targeted and biomarker-driven approach allows us to pursue a transformational drug development strategy that identifies, rescues or develops, and advances potential small molecule drug candidates at what we believe is a fraction of the time and cost associated with traditional cancer drug development.